$4.02 Billion is the total value of Casdin Capital, LLC's 54 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 29.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVTA | INVITAE CORP | $346,950,000 | -15.7% | 12,203,669 | 0.0% | 8.64% | -17.4% | |
| BLFS | Buy | BIOLIFE SOLUTIONS INC | $320,205,000 | -3.3% | 7,566,292 | +1.7% | 7.97% | -5.2% |
| EXAS | EXACT SCIENCES CORP | $225,280,000 | -23.2% | 2,360,186 | 0.0% | 5.61% | -24.7% | |
| PACB | Buy | PACIFIC BIOSCIENCES CALIF IN | $204,161,000 | +16.8% | 7,990,652 | +59.8% | 5.08% | +14.5% |
| FATE | FATE THERAPEUTICS INC | $201,518,000 | -31.7% | 3,400,000 | 0.0% | 5.02% | -33.0% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $188,810,000 | +11.4% | 1,000,000 | 0.0% | 4.70% | +9.2% | |
| New | MAXCYTE INC | $170,590,000 | – | 13,971,334 | +100.0% | 4.25% | – | |
| BPMC | BLUEPRINT MEDICINES CORP | $159,356,000 | +16.9% | 1,550,000 | 0.0% | 3.97% | +14.6% | |
| New | SOMALOGIC INC | $153,501,000 | – | 12,389,082 | +100.0% | 3.82% | – | |
| VERV | VERVE THERAPEUTICS INC | $142,794,000 | -22.0% | 3,038,167 | 0.0% | 3.55% | -23.5% | |
| RLAY | Buy | RELAY THERAPEUTICS INC | $115,670,000 | -6.3% | 3,668,574 | +8.7% | 2.88% | -8.2% |
| TWST | TWIST BIOSCIENCE CORP | $106,970,000 | -19.7% | 1,000,000 | 0.0% | 2.66% | -21.3% | |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $101,728,000 | +47.9% | 1,100,000 | +24.3% | 2.53% | +45.0% |
| CDXS | CODEXIS INC | $100,716,000 | +2.6% | 4,330,000 | 0.0% | 2.51% | +0.6% | |
| AGIO | AGIOS PHARMACEUTICALS INC | $99,915,000 | -16.3% | 2,165,000 | 0.0% | 2.49% | -17.9% | |
| New | ABSCI CORPORATION | $89,767,000 | – | 7,718,593 | +100.0% | 2.23% | – | |
| DNLI | Buy | DENALI THERAPEUTICS INC | $85,765,000 | -32.1% | 1,700,000 | +5.6% | 2.14% | -33.4% |
| New | GINKGO BIOWORKS HOLDINGS INC | $83,481,000 | – | 7,202,808 | +100.0% | 2.08% | – | |
| IPSC | CENTURY THERAPEUTICS INC | $80,673,000 | -14.2% | 3,206,380 | 0.0% | 2.01% | -15.9% | |
| RVMD | Buy | REVOLUTION MEDICINES INC | $77,028,000 | +5.3% | 2,800,000 | +21.5% | 1.92% | +3.2% |
| CDNA | CAREDX INC | $75,622,000 | -30.8% | 1,193,335 | 0.0% | 1.88% | -32.1% | |
| New | TENAYA THERAPEUTICS INC | $74,068,000 | – | 3,586,818 | +100.0% | 1.84% | – | |
| BEAM | BEAM THERAPEUTICS INC | $71,246,000 | -32.4% | 818,820 | 0.0% | 1.77% | -33.7% | |
| New | TANGO THERAPEUTICS INC | $70,959,000 | – | 5,487,910 | +100.0% | 1.77% | – | |
| DERMTECH INC | $56,032,000 | -22.8% | 1,745,000 | 0.0% | 1.40% | -24.2% | ||
| BGNE | BEIGENE LTDsponsored adr | $54,450,000 | +5.8% | 150,000 | 0.0% | 1.36% | +3.7% | |
| ALLO | Buy | ALLOGENE THERAPEUTICS INC | $53,970,000 | +68.9% | 2,100,000 | +71.4% | 1.34% | +65.6% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $49,049,000 | +6.9% | 1,925,000 | +46.9% | 1.22% | +4.8% |
| ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $48,946,000 | -16.8% | 1,440,000 | 0.0% | 1.22% | -18.5% | |
| New | SEMA4 HOLDINGS CORP | $37,950,000 | – | 5,000,000 | +100.0% | 0.94% | – | |
| ALEC | ALECTOR INC | $37,653,000 | +9.6% | 1,650,000 | 0.0% | 0.94% | +7.5% | |
| GBIO | Sell | GENERATION BIO CO | $33,200,000 | -23.4% | 1,324,275 | -17.8% | 0.83% | -24.9% |
| OMIC | SINGULAR GENOMICS SYSTEMS IN | $30,133,000 | -59.3% | 2,692,870 | 0.0% | 0.75% | -60.1% | |
| FDMT | Sell | 4D MOLECULAR THERAPEUTICS IN | $30,084,000 | +12.0% | 1,115,455 | -0.0% | 0.75% | +9.8% |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $29,822,000 | -30.9% | 266,430 | 0.0% | 0.74% | -32.2% | |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $28,404,000 | -13.2% | 3,901,589 | +16.6% | 0.71% | -14.9% |
| SNDX | SYNDAX PHARMACEUTICALS INC | $22,932,000 | +11.3% | 1,200,000 | 0.0% | 0.57% | +9.2% | |
| GLUE | MONTE ROSA THERAPEUTICS INC | $21,408,000 | -1.9% | 960,883 | 0.0% | 0.53% | -3.8% | |
| ZLAB | ZAI LAB LTDadr | $20,024,000 | -40.5% | 190,000 | 0.0% | 0.50% | -41.7% | |
| ME | Sell | 23ANDME HOLDING CO | $16,684,000 | -47.9% | 1,841,457 | -32.8% | 0.42% | -49.0% |
| MASS | 908 DEVICES INC | $13,219,000 | -16.1% | 406,502 | 0.0% | 0.33% | -17.8% | |
| RXRX | RECURSION PHARMACEUTICALS INcl a | $12,613,000 | -37.0% | 548,156 | 0.0% | 0.31% | -38.2% | |
| ORIC | ORIC PHARMACEUTICALS INC | $12,578,000 | +18.2% | 601,515 | 0.0% | 0.31% | +15.9% | |
| KRON | KRONOS BIO INC | $12,229,000 | -12.5% | 583,436 | 0.0% | 0.30% | -14.4% | |
| VRTX | New | VERTEX PHARMACEUTICALS INCcall | $9,070,000 | – | 50,000 | +100.0% | 0.23% | – |
| DBTX | Sell | DECIBEL THERAPEUTICS INC | $9,021,000 | -10.5% | 1,170,048 | -0.1% | 0.22% | -12.1% |
| TKNO | ALPHA TEKNOVA INC | $7,467,000 | +4.9% | 300,000 | 0.0% | 0.19% | +2.8% | |
| ORTX | Sell | ORCHARD THERAPEUTICS PLCads | $5,923,000 | -58.0% | 2,575,000 | -19.9% | 0.15% | -58.9% |
| SEER | SEER INC | $5,180,000 | +5.3% | 150,000 | 0.0% | 0.13% | +3.2% | |
| BLI | BERKELEY LTS INC | $3,912,000 | -56.3% | 200,000 | 0.0% | 0.10% | -57.3% | |
| STOK | STOKE THERAPEUTICS INC | $3,053,000 | -24.4% | 120,000 | 0.0% | 0.08% | -26.2% | |
| FHTX | Sell | FOGHORN THERAPEUTICS INC | $2,995,000 | +29.8% | 215,000 | -0.6% | 0.08% | +27.1% |
| NAUT | Sell | NAUTILUS BIOTECHNOLOGY INC | $1,382,000 | -72.6% | 225,000 | -55.0% | 0.03% | -73.4% |
| SANA | SANA BIOTECHNOLOGY INC | $1,351,000 | +14.5% | 60,000 | 0.0% | 0.03% | +13.3% | |
| ZY | Exit | ZYMERGEN INC | $0 | – | -30,000 | -100.0% | -0.03% | – |
| TPTX | Exit | TURNING POINT THERAPEUTICS I | $0 | – | -75,000 | -100.0% | -0.15% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -550,000 | -100.0% | -0.17% | – |
| CLOV | Exit | CLOVER HEALTH INVESTMENTS CO | $0 | – | -726,511 | -100.0% | -0.25% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -1,154,476 | -100.0% | -0.31% | – |
| NEO | Exit | NEOGENOMICS INC | $0 | – | -488,889 | -100.0% | -0.56% | – |
| CNST | Exit | CONSTELLATION PHARMCETICLS I | $0 | – | -1,341,000 | -100.0% | -1.15% | – |
| AMRS | Exit | AMYRIS INC | $0 | – | -3,000,000 | -100.0% | -1.25% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.